Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-γ production

Blood

Volumn 90, Issue 7, 1997, Pages 2541-2548

  Leonard, John P ^b   Sherman, Matthew L ^b   Fisher, Gerald L ^b   Buchanan, Lynn J ^b   Larsen, Glenn ^b   Atkins, Michael B ^b   Sosman, Jeffrey A ^b   Dutcher, Janice P ^b   Vogelzang, Nicholas J ^b   Ryan, John L ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ACIDOSIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG EFFECT; DRUG SAFETY; DRUG USE; DYSPNEA; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; COLITIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C3H; MIDDLE AGED; RECOMBINANT PROTEINS; SAFETY; STOMATITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030766971     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kobayashi M, Fitz L, Ryan M, Hewick RR, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 170:827, 1989
2. Trinchieri G: Interleukin 12: A cytokine produced by antigen presenting cells with immunoregulatory functions in the generation of T helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008, 1994
3. Brunda MJ: Interleukin 12. J Leukocyte Biol 55:280, 1994
4. Wolf SF, Sieburth D, Sypek J: Interleukin 12: A key modulator of immune function. Stem Cells 12:154, 1994
5. Brunda MJ, Lusitro L, Warrior R, Wright BB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223, 1993
6. Nastala CL, Edington HG, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gatery MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-y production. J Immunol 153:1697, 1994
7. Zou J-P, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol 7:1135, 1995
8. Noguchi Y, Richards EC, Chen Y-T, Old LJ: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219, 1995
9. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK: Role of interferon-γ in mediating the antitumor efficacy of interleukin 12. J Immunother 17:71, 1995
10. Sarmiento UM, Riley JH, Knack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD: Biologic effects of recombinant interleukin 12 in squirrel monkeys. Lab Invest 71:862, 1994
11. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ: Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun 204:1150, 1994
12. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML: Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin Cancer Res 3:409, 1997
13. Creekmore SP, Urba WJ, Longo DL: Principles of the clinical evaluation of biologic agents, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991 p 76
14. Murray KS, Garzone P, Wiencis AM, Kolowsky ML, Velikovic A, Celniker A, VanCleave V: Chemiluminescent-based ELISA for IL-12: High sensitivity permits pharmacokinetics analysis. Ninth International Congress of Immunology. San Francisco, CA, July 23-29, 1995, abstr 130, p 23
15. Kurzrock R, Rosenblum MG, Sherwin, SA, Rios A, Talpaz M, Quesada JR, Gutterman JU: Pharmacokinetics, single-dose tolerance, and biological activity of recombinant γ-interferon in cancer patients. Cancer Res 45:2866, 1985
16. Foon K, Sherwin S, Abrahms P, Stevenson H, Holmes P, Maluish A, Oldham R, Herberman R: A phase 1 trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 20:193, 1985
17. Kurzrock R, Quesada JR, Rosenblum, Sherwin SA, Gutterman JU: Phase I study of IV administered recombinant gamma Interferon in cancer patients. Cancer Treat Rep 70:1357, 1986
18. Kurzrock R, Quesada JR, Talpaz M: Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 4:1101, 1986
19. Vadham RS, Al-Katib A, Bhalla R: Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 4:137, 1986
20. Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A: Subcutaneous recombinant gamma interferon in cancer patients: Toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 25:47, 1987
21. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU: Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 6:20, 1987
22. Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Balser J, Rudnick S, Kirkwood JM: A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 5:1804, 1987
23. Garnick MB, Reich SD, Maxwell B, Coval-Goldsmith S, Richie JP, Rudnick SA: Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 139:251, 1988
24. Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG: The determination of an immunologically active dose of interferongamma in patients with melanoma. J Clin Oncol 6:434, 1988
25. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281, 1995
26. Naume B, Gately MK, Espevik T: A comparative study of IL-12 (cytotoxic lymphocyte maturation factor), IL-2, and IL-7 induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 148:2429, 1992
27. Morris SC, Madden KB, Adamovicz JJ, Cause WC, Hubbard BR, Gately MK, Finkelman FD: Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 152:1047, 1994
28. Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiological antagonist. Proc Natl Acad Sci USA 90:3725, 1993
29. Henderson DC, Sheldon J, Riches P, Hobbs JR: Cytokine induction of neopterin production. Clin Exp Immunol 83:479, 1991
30. Terrell TG, Green JD: Comparative pathology of recombinant murine interferon-γ in mice and recombinant human interferon-γ in cynomolgus monkeys. Int Rev Exp Pathol 34B:73, 1993
31. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W: Recombinant tumor necrosis factor: Its effect and synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22:419, 1986
32. Broukaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W: In vivo antitumor activity of recombinant human and murine TNF. alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 38:763, 1986
33. Wallach D, Holtmann H, Engelmann H, Nophar Y: Sensitization and desensitization to the lethal effects of tumor necrosis factor and IL-1. J Immunol 140:2994, 1988